FGFR genes mutation is an independent prognostic factor and associated with lymph node metastasis in squamous non-small cell lung cancer

References

• Global Burden of Disease Cancer C, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, et al. The Global Burden of Cancer 2013. JAMA oncology. 2015;1:505–527. doi:10.1001/jamaoncol.2015.0735.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Heymach JV, Lippman SM. Lung cancer. New Eng J Med. 2008;359:1367–1380. doi:10.1056/NEJMra0802714.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–525. doi:10.1038/nature11404.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–550. doi:10.1038/nature13385.
   PubMed Web of Science ®Google Scholar
• Moreira AL, Eng J. Personalized therapy for lung cancer. Chest. 2014;146:1649–1657. doi:10.1378/chest.14-0713.
   PubMed Web of Science ®Google Scholar
• Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non–small-cell lung cancer with Erlotinib or Gefitinib. New Eng J Med. 2011;364:947–955. doi:10.1056/NEJMct0807960.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, et al. Rociletinib in EGFR-mutated non–small-cell lung cancer. N Engl J Med. 2015;372:1700–1709. doi:10.1056/NEJMoa1413654.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim D-W, Wu Y-L, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New Eng J Med. 2014;371:2167–2177. doi:10.1056/NEJMoa1408440.
   PubMed Web of Science ®Google Scholar
• Drilon A, Rekhtman N, Ladanyi M, Paik P. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol. 2012;13:e418–26. doi:10.1016/S1470-2045(12)70291-7.
   PubMed Web of Science ®Google Scholar
• Greulich H, Pollock PM. Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med. 2011;17:283–292. doi:10.1016/j.molmed.2011.01.012.
   PubMed Web of Science ®Google Scholar
• Filipits M. New developments in the treatment of squamous cell lung cancer. Curr Opin Oncol. 2014;26:152–158. doi:10.1097/CCO.0000000000000049.
   PubMed Web of Science ®Google Scholar
• Semrad TJ, Mack PC. Fibroblast growth factor signaling in non–small-cell lung cancer. Clin Lung Cancer. 2012;13:90–95. doi:10.1016/j.cllc.2011.08.001.
   PubMed Web of Science ®Google Scholar
• Gartside MG, Chen H, Ibrahimi OA, Byron SA, Curtis AV, Wellens CL, Bengston A, Yudt LM, Eliseenkova AV, Ma J, et al. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res. 2009;7:41–54. doi:10.1158/1541-7786.MCR-08-0021.
   PubMed Web of Science ®Google Scholar
• Taylor J, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, Yu Y, Chen Q-R, Shah K, Youngblood V, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest. 2009;119:3395–3407. doi:10.1172/JCI39703.
   PubMed Web of Science ®Google Scholar
• Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science translational medicine. 2010;2:62ra93. doi:10.1126/scitranslmed.3001451.
   PubMed Web of Science ®Google Scholar
• Liao RG, Jung J, Tchaicha J, Wilkerson MD, Sivachenko A, Beauchamp EM, Liu Q, Pugh TJ, Pedamallu CS, Hayes DN, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013;73:5195–5205. doi:10.1158/0008-5472.CAN-12-3950.
   PubMed Web of Science ®Google Scholar
• Di Stefano AL, Fucci A, Frattini V, Labussiere M, Mokhtari K, Zoppoli P, Marie Y, Bruno A, Boisselier B, Giry M, et al. Detection, characterization and inhibition of FGFR-TACC fusions in IDH wild type glioma. Clin Cancer Res. 2015;21:3307–3317. doi:10.1158/1078-0432.CCR-14-2199.
   PubMed Web of Science ®Google Scholar
• Shotelersuk V, Ittiwut C, Srivuthana S, Mahatumarat C, Lerdlum S, Wacharasindhu S. Distinct craniofacial-skeletal-dermatological dysplasia in a patient with W290C mutation in FGFR2. Am J Med Genet. 2002;113:4–8. doi:10.1002/ajmg.10449.
   PubMed Web of Science ®Google Scholar
• Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, Teague J, Butler A, Edkins S, Stevens C, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005;65:7591–7595. doi:10.1158/0008-5472.CAN-05-1855.
   PubMed Web of Science ®Google Scholar
• Dodurga Y, Tataroglu C, Kesen Z, Satiroglu-Tufan NL. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer. Genet Mol Res. 2011;10:86–95. doi:10.4238/vol10-1gmr923.
   PubMed Web of Science ®Google Scholar
• Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One. 2011;6:e20351. doi:10.1371/journal.pone.0020351.
   PubMed Web of Science ®Google Scholar
• Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, et al. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res. 2014;20:3299–3309. doi:10.1158/1078-0432.CCR-13-3060.
   PubMed Web of Science ®Google Scholar
• Tiseo M, Gelsomino F, Alfieri R, Cavazzoni A, Bozzetti C, De Giorgi AM, Petronini PG, Ardizzoni A. FGFR as potential target in the treatment of squamous non small cell lung cancer. Cancer Treat Rev. 2015;41:527–539. doi:10.1016/j.ctrv.2015.04.011.
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–714. doi:10.1097/JTO.0b013e31812f3c1a.
   PubMed Web of Science ®Google Scholar
• Hiltemann S, Jenster G, Trapman J, Van Der Spek P, Stubbs A. Discriminating somatic and germline mutations in tumor DNA samples without matching normals. Genome Res. 2015;25:1382–1390. doi:10.1101/gr.183053.114.
   PubMed Web of Science ®Google Scholar
• Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, Rozen SG. Primer3–new capabilities and interfaces. Nucleic Acids Res. 2012;40:e115. doi:10.1093/nar/gks596.
   PubMed Web of Science ®Google Scholar
• Vaser R, Adusumalli S, Leng SN, Sikic M, Ng PC. SIFT missense predictions for genomes. Nat Protoc. 2016;11:1–9. doi:10.1038/nprot.2015.123.
   PubMed Web of Science ®Google Scholar
• Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 2012;40:W452–7. doi:10.1093/nar/gks539.
   PubMed Web of Science ®Google Scholar
• Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet/Edit Board, Jonathan L Haines [et al]. 2013;Chapter 7:Unit720.
   Google Scholar
• Gudernova I, Vesela I, Balek L, Buchtova M, Dosedelova H, Kunova M, Pivnicka J, Jelinkova I, Roubalova L, Kozubik A, et al. Multikinase activity of fibroblast growth factor receptor (FGFR) inhibitors SU5402, PD173074, AZD1480, AZD4547 and BGJ398 compromises the use of small chemicals targeting FGFR catalytic activity for therapy of short stature syndromes. Hum Mol Genet. 2016; 25:9–23.
   PubMed Web of Science ®Google Scholar
• Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res. 2013;19:2572–2583. doi:10.1158/1078-0432.CCR-12-3898.
   PubMed Web of Science ®Google Scholar
• Ren M, Hong M, Liu G, Wang H, Patel V, Biddinger P, Silva J, Cowell J, Hao Z. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. Oncol Rep. 2013;29:2181–2190. doi:10.3892/or.2013.2386.
   PubMed Web of Science ®Google Scholar
• Andre F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013;19:3693–3702. doi:10.1158/1078-0432.CCR-13-0190.
   PubMed Web of Science ®Google Scholar
• Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA. 2008;105:8713–8717. doi:10.1073/pnas.0803379105.
   PubMed Web of Science ®Google Scholar
• Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4,853 tumors by Next-Generation sequencing. Clinical Cancer Research. 2016; 22:259–267.
   PubMedGoogle Scholar
• Wang R, Zhang Y, Pan Y, Li Y, Hu H, Cai D, Li H, Ye T, Luo X, Zhang Y, et al. Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. Oncotarget. 2015; 6:34300–34308.
   Google Scholar
• Tanizaki J, Ercan D, Capelletti M, Dodge M, Xu C, Bahcall M, Tricker EM, Butaney M, Calles A, Sholl LM, et al. Identification of oncogenic and drug-sensitizing mutations in the extracellular domain of FGFR2. Cancer Res. 2015;75:3139–3146. doi:10.1158/0008-5472.CAN-14-3771.
   PubMed Web of Science ®Google Scholar
• Lajeunie E, Heuertz S, El Ghouzzi V, Martinovic J, Renier D, Le Merrer M, Bonaventure J. Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome. Eur J Hum Genet. 2006;14:289–298. doi:10.1038/sj.ejhg.5201558.
   PubMed Web of Science ®Google Scholar
• Falvella FS, Frullanti E, Galvan A, Spinola M, Noci S, De Cecco L, Nosotti M, Santambrogio L, Incarbone M, Alloisio M, et al. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung. Int J Cancer. 2009;124:2880–2885. doi:10.1002/ijc.24302.
   PubMed Web of Science ®Google Scholar
• Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U, Dragani TA. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol. 2005;23:7307–7311. doi:10.1200/JCO.2005.17.350.
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder, S, Wang, Z, Welch, R, Hutchinson, A, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39:870–874. doi:10.1038/ng2075.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Sun S, Wei W, Ren Y, Liu J, Pang D. Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province. Oncotarget. 2015;6:34023–34029. doi:10.18632/oncotarget.5850.
   PubMedGoogle Scholar
• Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer. 2014;14:173–186. doi:10.1038/nrc3680.
   PubMed Web of Science ®Google Scholar
• Zhou J, Song XB, He H, Zhou Y, Lu XJ, Ying BW. Prevalence and clinical profile of EGFR mutation in non- small-cell lung carcinoma patients in Southwest China. Asian Pac J Cancer Prev. 17;2016:965–971.
   PubMedGoogle Scholar
• Touat M, Ileana E, Postel-Vinay S, Andre F, Soria JC. Targeting FGFR signaling in cancer. Clin Cancer Res. 2015;21:2684–2694. doi:10.1158/1078-0432.CCR-14-2329.
   PubMed Web of Science ®Google Scholar